Protection from chemotherapy-induced neutropenia by ImuVert

Joaquin J Jimenez, H. S. Huang, M. Hindahl, F. C. Pearson, Adel A Yunis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neutropenia is a major cause of chemotherapy-induced morbidity. This study examines the effect of ImuVert on the course of neutropenia from Cytoxan and Adriamycin. In adult rats treated with either Cytoxan or Adriamycin and ImuVert, the absolute neutrophil count remained above 7,000 and 2,000, respectively, for the duration of ImuVert therapy. In contrast, in the control Cytoxan group the absolute neutrophil count reached 300/mm3 on day 5 and remained below 1,000 from day 4 through day 7. In the Adriamycin control group, the nadir absolute neutrophil count reached 600/mm3 on day 7 and remained below 100 from day 6 through day 8. C3H/EJ mice (endotoxin-hypo- responsive) treated with Cytoxan developed an absolute neutrophil count below 1,000 from day 4 through day 7. In contrast, in the group concomitantly treated with ImuVert, the nadir absolute neutrophil count remained below 1,000 only on days 4 and 5. The authors conclude that stimulation of endogenous cytokine production by ImuVert may provide a potentially useful approach to bone marrow rescue from chemotherapy.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalAmerican Journal of the Medical Sciences
Volume303
Issue number2
StatePublished - Jan 1 1992

Fingerprint

Neutropenia
Neutrophils
Cyclophosphamide
Drug Therapy
Doxorubicin
Control Groups
Inbred C3H Mouse
Endotoxins
Bone Marrow
ImuVert
Cytokines
Morbidity
Therapeutics

Keywords

  • Adriamycin
  • Biologic response modifier
  • Cytoxan
  • Myelosuppression
  • Neutropenia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jimenez, J. J., Huang, H. S., Hindahl, M., Pearson, F. C., & Yunis, A. A. (1992). Protection from chemotherapy-induced neutropenia by ImuVert. American Journal of the Medical Sciences, 303(2), 83-85.

Protection from chemotherapy-induced neutropenia by ImuVert. / Jimenez, Joaquin J; Huang, H. S.; Hindahl, M.; Pearson, F. C.; Yunis, Adel A.

In: American Journal of the Medical Sciences, Vol. 303, No. 2, 01.01.1992, p. 83-85.

Research output: Contribution to journalArticle

Jimenez, JJ, Huang, HS, Hindahl, M, Pearson, FC & Yunis, AA 1992, 'Protection from chemotherapy-induced neutropenia by ImuVert', American Journal of the Medical Sciences, vol. 303, no. 2, pp. 83-85.
Jimenez JJ, Huang HS, Hindahl M, Pearson FC, Yunis AA. Protection from chemotherapy-induced neutropenia by ImuVert. American Journal of the Medical Sciences. 1992 Jan 1;303(2):83-85.
Jimenez, Joaquin J ; Huang, H. S. ; Hindahl, M. ; Pearson, F. C. ; Yunis, Adel A. / Protection from chemotherapy-induced neutropenia by ImuVert. In: American Journal of the Medical Sciences. 1992 ; Vol. 303, No. 2. pp. 83-85.
@article{fcd8511bdfa74045bdaadbf4b3fa4591,
title = "Protection from chemotherapy-induced neutropenia by ImuVert",
abstract = "Neutropenia is a major cause of chemotherapy-induced morbidity. This study examines the effect of ImuVert on the course of neutropenia from Cytoxan and Adriamycin. In adult rats treated with either Cytoxan or Adriamycin and ImuVert, the absolute neutrophil count remained above 7,000 and 2,000, respectively, for the duration of ImuVert therapy. In contrast, in the control Cytoxan group the absolute neutrophil count reached 300/mm3 on day 5 and remained below 1,000 from day 4 through day 7. In the Adriamycin control group, the nadir absolute neutrophil count reached 600/mm3 on day 7 and remained below 100 from day 6 through day 8. C3H/EJ mice (endotoxin-hypo- responsive) treated with Cytoxan developed an absolute neutrophil count below 1,000 from day 4 through day 7. In contrast, in the group concomitantly treated with ImuVert, the nadir absolute neutrophil count remained below 1,000 only on days 4 and 5. The authors conclude that stimulation of endogenous cytokine production by ImuVert may provide a potentially useful approach to bone marrow rescue from chemotherapy.",
keywords = "Adriamycin, Biologic response modifier, Cytoxan, Myelosuppression, Neutropenia",
author = "Jimenez, {Joaquin J} and Huang, {H. S.} and M. Hindahl and Pearson, {F. C.} and Yunis, {Adel A}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "303",
pages = "83--85",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Protection from chemotherapy-induced neutropenia by ImuVert

AU - Jimenez, Joaquin J

AU - Huang, H. S.

AU - Hindahl, M.

AU - Pearson, F. C.

AU - Yunis, Adel A

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Neutropenia is a major cause of chemotherapy-induced morbidity. This study examines the effect of ImuVert on the course of neutropenia from Cytoxan and Adriamycin. In adult rats treated with either Cytoxan or Adriamycin and ImuVert, the absolute neutrophil count remained above 7,000 and 2,000, respectively, for the duration of ImuVert therapy. In contrast, in the control Cytoxan group the absolute neutrophil count reached 300/mm3 on day 5 and remained below 1,000 from day 4 through day 7. In the Adriamycin control group, the nadir absolute neutrophil count reached 600/mm3 on day 7 and remained below 100 from day 6 through day 8. C3H/EJ mice (endotoxin-hypo- responsive) treated with Cytoxan developed an absolute neutrophil count below 1,000 from day 4 through day 7. In contrast, in the group concomitantly treated with ImuVert, the nadir absolute neutrophil count remained below 1,000 only on days 4 and 5. The authors conclude that stimulation of endogenous cytokine production by ImuVert may provide a potentially useful approach to bone marrow rescue from chemotherapy.

AB - Neutropenia is a major cause of chemotherapy-induced morbidity. This study examines the effect of ImuVert on the course of neutropenia from Cytoxan and Adriamycin. In adult rats treated with either Cytoxan or Adriamycin and ImuVert, the absolute neutrophil count remained above 7,000 and 2,000, respectively, for the duration of ImuVert therapy. In contrast, in the control Cytoxan group the absolute neutrophil count reached 300/mm3 on day 5 and remained below 1,000 from day 4 through day 7. In the Adriamycin control group, the nadir absolute neutrophil count reached 600/mm3 on day 7 and remained below 100 from day 6 through day 8. C3H/EJ mice (endotoxin-hypo- responsive) treated with Cytoxan developed an absolute neutrophil count below 1,000 from day 4 through day 7. In contrast, in the group concomitantly treated with ImuVert, the nadir absolute neutrophil count remained below 1,000 only on days 4 and 5. The authors conclude that stimulation of endogenous cytokine production by ImuVert may provide a potentially useful approach to bone marrow rescue from chemotherapy.

KW - Adriamycin

KW - Biologic response modifier

KW - Cytoxan

KW - Myelosuppression

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0026527426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026527426&partnerID=8YFLogxK

M3 - Article

VL - 303

SP - 83

EP - 85

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -